Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Richard F. Pollock, Fabien Colaone, Laura Guardiola, Suki Shergill & Victoria K. Brennan. (2020) A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK. Journal of Medical Economics 23:6, pages 593-602.
Read now
Read now
Richard W. Joseph, Alicia C. Shillington, Todd A. Lee, Cynthia P. Macahilig, Scott J. Diede, Vaidehi Dave, Qing Harshaw, Emilie Scherrer & Frank Xiaoqing Liu. (2020) Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers. Journal of Medical Economics 23:2, pages 132-138.
Read now
Read now
Christos Chouaid, Delphine Loirat, Emilie Clay, Aurélie Millier, Chloé Godard, Amira Fannan, Laurie Lévy-Bachelot & Eric Angevin. (2017) Cost analysis of adverse events associated with non-small cell lung cancer management in France. ClinicoEconomics and Outcomes Research 9, pages 443-449.
Read now
Read now
Articles from other publishers (21)
Ganesh Vambhurkar, Paras Famta, Saurabh Shah, Naitik Jain, Dadi A. Srinivasarao, Anamika Sharma, Syed Shahrukh, Dharmendra Kumar Khatri, Shashi Bala Singh & Saurabh Srivastava. (2023) Quality by Design (QbD) Galvanized development of resveratrol loaded PLGA nanoparticles: In vitro and Ex vivo evaluation for the non-invasive treatment of metastatic melanoma. Journal of Drug Delivery Science and Technology, pages 105252.
Crossref
Crossref
Sarah B. Bateni, Paul Nguyen, Antoine Eskander, Soo Jin Seung, Nicole Mittmann, Matthew Jalink, Arjun Gupta, Kelvin K. W. Chan, Nicole J. Look Hong & Timothy P. Hanna. (2023) Changes in Health Care Costs, Survival, and Time Toxicity in the Era of Immunotherapy and Targeted Systemic Therapy for Melanoma. JAMA Dermatology 159:11, pages 1195.
Crossref
Crossref
Jean-Baptiste Trouiller, Georgios F. Nikolaidis, Bérengère Macabeo, Nicolas Meyer, Laetitia Gerlier, Max Schlueter & Philippe Laramee. (2023) Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma. The European Journal of Health Economics.
Crossref
Crossref
Francesca Fiorentino & Paolo Di Rienzo. (2023) Budget impact analysis of enzalutamide for the treatment of hormone-sensitive metastatic prostate cancer in Italy. Global & Regional Health Technology Assessment 10, pages 29-39.
Crossref
Crossref
Haijing Guan, Chunping Wang, Chen Chen, Sheng Han & Zhigang Zhao. (2022) Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China. Frontiers in Oncology 12.
Crossref
Crossref
Kei Teramoto, Toshihiro Takeda, Naoki Mihara, Yoshie Shimai, Shirou Manabe, Shigeki Kuwata, Hiroshi Kondoh & Yasushi Matsumura. (2021) Detecting Adverse Drug Events Through the Chronological Relationship Between the Medication Period and the Presence of Adverse Reactions From Electronic Medical Record Systems: Observational Study. JMIR Medical Informatics 9:11, pages e28763.
Crossref
Crossref
Duygu Sezen, Vivek Verma, Kewen He, Chike O. Abana, Hampartsaum Barsoumian, Matthew S. Ning, Chad Tang, Pervin Hurmuz, Nahum Puebla-Osorio, Dawei Chen, Irwin Tendler, Nathan Comeaux, Quynh-Nhu Nguyen, Joe Y Chang & James W. Welsh. (2021) Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease. Seminars in Radiation Oncology 31:3, pages 217-226.
Crossref
Crossref
Tao Cheng, Zhiheng Zhang, Hua Shen, Ziying Jian, Junsheng Li, Yujun Chen, Yi Shen & Xinyi Dai. (2020) Topically applicated curcumin/gelatin-blended nanofibrous mat inhibits pancreatic adenocarcinoma by increasing ROS production and endoplasmic reticulum stress mediated apoptosis. Journal of Nanobiotechnology 18:1.
Crossref
Crossref
Kate R. Secombe, Ysabella Z. A. Van Sebille, Bronwen J. Mayo, Janet K. Coller, Rachel J. Gibson & Joanne M. Bowen. (2020) Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome. Integrative Cancer Therapies 19, pages 153473542092849.
Crossref
Crossref
Anna Luiza S.A. Vicente, Camila S. Crovador, Graziela Macedo, Cristovam Scapulatempo-Neto, Rui M. Reis & Vinicius L. Vazquez. (2019) Mutational Profile of Driver Genes in Brazilian Melanomas. Journal of Global Oncology:5, pages 1-14.
Crossref
Crossref
Ying Wang, Pierre Camateros, Denise Smith, David Dawe & Peter Ellis. (2019) Immunotherapy with check-point inhibitors (CPI) in adult malignancies: a protocol for the systematic review of the quality of economic analyses. Systematic Reviews 8:1.
Crossref
Crossref
Ash Bullement, Paul Nathan, Anna Willis, Amerah Amin, Cameron Lilley, Ceilidh Stapelkamp, Anthony Hatswell, Chris Pescott & Murtuza Bharmal. (2019) Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma. PharmacoEconomics - Open 3:3, pages 377-390.
Crossref
Crossref
Kate R. Secombe, Janet K. Coller, Rachel J. Gibson, Hannah R. Wardill & Joanne M. Bowen. (2018) The bidirectional interaction of the gut microbiome and the innate immune system: Implications for chemotherapy‐induced gastrointestinal toxicity. International Journal of Cancer 144:10, pages 2365-2376.
Crossref
Crossref
Francesco S. Mennini, Chiara Bini, Andrea Marcellusi & Michele Del Vecchio. (2018) Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma. Clinical Drug Investigation 38:10, pages 967-976.
Crossref
Crossref
Alex Z Fu, Zhiyi Li, Jackson Tang, Syed Mahmood, Tyler Whisman & Ying Qiu. (2018) Costs associated with adverse events for systemic therapies in metastatic melanoma. Journal of Comparative Effectiveness Research 7:9, pages 867-879.
Crossref
Crossref
Catherine Copley-Merriman, Kendall Stevinson, Frank Xiaoqing Liu, Jingshu Wang, Josephine Mauskopf, Evelina A. Zimovetz & Bartosz Chmielowski. (2018) Direct costs associated with adverse events of systemic therapies for advanced melanoma. Medicine 97:31, pages e11736.
Crossref
Crossref
S. Khan, Hannah R. Wardill & J. M. Bowen. (2018) Role of toll-like receptor 4 (TLR4)-mediated interleukin-6 (IL-6) production in chemotherapy-induced mucositis. Cancer Chemotherapy and Pharmacology 82:1, pages 31-37.
Crossref
Crossref
Yoshie Shimai, Toshihiro Takeda, Katsuki Okada, Shirou Manabe, Kei Teramoto, Naoki Mihara & Yasushi Matsumura. (2018) Screening of anticancer drugs to detect drug-induced interstitial pneumonia using the accumulated data in the electronic medical record. Pharmacology Research & Perspectives 6:4, pages e00421.
Crossref
Crossref
William Wong, Yeun Mi Yim, Ashley Kim, Martin Cloutier, Marjolaine Gauthier-Loiselle, Patrick Gagnon-Sanschagrin & Annie Guerin. (2018) Assessment of costs associated with adverse events in patients with cancer. PLOS ONE 13:4, pages e0196007.
Crossref
Crossref
Mahdi Zargar, Thomas McFarlane, Kelvin K.W. Chan & William W.L. Wong. (2018) Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma. The Oncologist 23:2, pages 225-233.
Crossref
Crossref
Clara Curiel-Lewandrowski & Susan M. Swetter. (2016) Lack of harms from community-based melanoma screening by primary care providers. Cancer 122:20, pages 3102-3105.
Crossref
Crossref